Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of HematologyGlobeNewsWire • 11/04/20
Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020GlobeNewsWire • 10/27/20
Allogene Therapeutics Announces October 2020 Virtual Investor Conference ParticipationGlobeNewsWire • 10/01/20
Allogene Therapeutics (ALLO) Down 9.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/04/20
Allogene Therapeutics Announces September 2020 Virtual Investor Conference ParticipationGlobeNewsWire • 09/02/20
Allogene Therapeutics' (ALLO) CEO David Chang on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020GlobeNewsWire • 07/28/20
Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D.GlobeNewsWire • 07/07/20
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin PrizeGlobeNewsWire • 07/01/20
Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Research (AACR) Virtual 2020 MeetingGlobeNewsWire • 06/22/20
Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid LeukemiaGlobeNewsWire • 06/22/20
Has Allogene Therapeutics (ALLO) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 06/10/20
Why Is Allogene Therapeutics (ALLO) Up 40.6% Since Last Earnings Report?Zacks Investment Research • 06/05/20
Allogene Therapeutics Announces Commencement of Public Offering of Common StockGlobeNewsWire • 06/01/20
Is Allogene Therapeutics (ALLO) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 05/22/20